Ildong Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Ildong Pharmaceutical has a total shareholder equity of ₩177.3B and total debt of ₩193.3B, which brings its debt-to-equity ratio to 109%. Its total assets and total liabilities are ₩600.9B and ₩423.6B respectively.
Key information
109.0%
Debt to equity ratio
₩193.27b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩73.34b |
| Equity | ₩177.31b |
| Total liabilities | ₩423.60b |
| Total assets | ₩600.91b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: A249420's short term assets (₩233.7B) do not cover its short term liabilities (₩274.6B).
Long Term Liabilities: A249420's short term assets (₩233.7B) exceed its long term liabilities (₩149.0B).
Debt to Equity History and Analysis
Debt Level: A249420's net debt to equity ratio (67.6%) is considered high.
Reducing Debt: A249420's debt to equity ratio has increased from 46.9% to 109% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A249420 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A249420 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.